Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Does measurement of 18F-fluoride metabolic flux improve response assessment of breast cancer bone metastases compared with standardised uptake values in 18F-fluoride PET/CT?

Azad G, Siddique MM, Taylor B, Green A, O'Doherty J, Gariani J, Blake GM, Mansi J, Goh V, Cook GJR.

J Nucl Med. 2018 Jul 24. pii: jnumed.118.208710. doi: 10.2967/jnumed.118.208710. [Epub ahead of print]

PMID:
30042160
2.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
3.

The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics".

Dangoor A, Joffe J, Januszewski A, Mansi J, Cunningham D, Selby P; 17 other authors and members of the Association of Cancer Physicians, UK.

BMJ. 2016 Dec 5;355:i6487. doi: 10.1136/bmj.i6487. No abstract available.

PMID:
27920029
4.

An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients.

Baird R, Banks I, Cameron D, Chester J, Earl H, Flannagan M, Januszewski A, Kennedy R, Payne S, Samuel E, Taylor H, Agarwal R, Ahmed S, Archer C, Board R, Carser J, Copson E, Cunningham D, Coleman R, Dangoor A, Dark G, Eccles D, Gallagher C, Glaser A, Griffiths R, Hall G, Hall M, Harari D, Hawkins M, Hill M, Johnson P, Jones A, Kalsi T, Karapanagiotou E, Kemp Z, Mansi J, Marshall E, Mitchell A, Moe M, Michie C, Neal R, Newsom-Davis T, Norton A, Osborne R, Patel G, Radford J, Ring A, Shaw E, Skinner R, Stark D, Turnbull S, Velikova G, White J, Young A, Joffe J, Selby P.

Ecancermedicalscience. 2016 Jan 5;10:608. doi: 10.3332/ecancer.2016.608. eCollection 2016.

5.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.

PMID:
26874901
6.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, Williams C, Kitchener H, Osborne R, Guthrie D, Harper P, Bliss JM.

J Clin Oncol. 2015 Dec 10;33(35):4138-44. doi: 10.1200/JCO.2015.60.9719. Epub 2015 Sep 28.

PMID:
26417001
7.

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.

Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, Mansi J, Harries M, Tutt A, Goh V.

Radiology. 2014 Jul;272(1):100-12. doi: 10.1148/radiol.14130569. Epub 2014 Mar 19.

PMID:
24654970
8.

Discordance between cancer prevalence and training: a need for an increase in oncology education.

Payne S, Burke D, Mansi J, Jones A, Norton A, Joffe J, Cunningham D, McVie G, Agarwal R.

Clin Med (Lond). 2013 Feb;13(1):50-6.

PMID:
23472496
9.

Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.

Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR.

Breast Cancer Res Treat. 2010 Aug;122(3):787-94. doi: 10.1007/s10549-010-0989-6. Epub 2010 Jun 18.

PMID:
20559708
10.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG.

N Engl J Med. 2006 Nov 2;355(18):1851-62.

11.

Vitamin D status and breast cancer risk.

Colston KW, Lowe LC, Mansi JL, Campbell MJ.

Anticancer Res. 2006 Jul-Aug;26(4A):2573-80.

12.

Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.

Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW, Campbell MJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2004-13.

13.

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M.

J Clin Oncol. 2005 Sep 20;23(27):6674-81.

PMID:
16170175
14.

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC.

Lancet Oncol. 2005 Jun;6(6):383-91. Erratum in: Lancet Oncol. 2005 Jun;6(6):357.

PMID:
15925816
15.

Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population.

Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW.

Eur J Cancer. 2005 May;41(8):1164-9. Epub 2005 Apr 14.

PMID:
15911240
16.

Autocrine metabolism of vitamin D in normal and malignant breast tissue.

Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M.

Clin Cancer Res. 2005 May 1;11(9):3579-86.

17.

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.

Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL.

J Clin Oncol. 2005 May 1;23(13):2988-95.

PMID:
15860854
18.

Vitamin D receptor gene polymorphisms and breast cancer risk.

Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, Wilson RG, Thomas V, Colston KW.

Clin Cancer Res. 2004 Aug 15;10(16):5472-81.

19.

The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival.

Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC.

Clin Cancer Res. 2004 Apr 1;10(7):2421-8.

20.

Approaches to evaluating the association of vitamin D receptor gene polymorphisms with breast cancer risk.

Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Colston KW.

Recent Results Cancer Res. 2003;164:43-54. Review.

PMID:
12899513

Supplemental Content

Loading ...
Support Center